Platform & Strategies

Publications

HomePlatform & StrategiesPublications

논문 검색 폼 search
게시물 목록(NO,Pipeline,Name,Title,PDF)
NO Pipeline Name Title PDF
25 ABL503 ASCO2024 Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors PDF 아이콘
24 ABL503 SITC 2023 ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade PDF 아이콘
23 ABL105 AACR 2024 The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-1 antibody PDF 아이콘
22 ABL407 AACR2024 ABL407, a LILRB4x4-1BB Bispecific Antibody with a Wild Type Fc, Exhibits Potent Antitumor Activity by Modulating Immune System in Multiple Ways Involving T cells, Myeloids, and Regulatory T cells PDF 아이콘
21 ABL112 AACR2024 A Novel TIGIT and 4-1BB Bispecific Antibody, ABL112, Exhibits Potent in vitroand in vivo Antitumor Activity Through Dual Immune Modulation PDF 아이콘
20 ABL103 PEGS Europe 2023 PEGS Europe 2023 / ABL103, a novel B7-H4x4-1BB bispecific antibody, exerts potent antitumor activity and good safety profile via B7-H4-dependent 4-1BB activation with increased immune cell infiltration in tumor microenvironment PDF 아이콘
19 ABL102 PEGS Europe 2023 PEGS Europe 2023 / ROR1 targeted 4-1BB conditional bispecific antibody, ABL102, exhibits potent in vitro and in vivo antitumor activity and superior safety profile PDF 아이콘
18 Neuroscience CVB2023 CVB2023 / Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier PDF 아이콘
17 ABL102 AACR2023 AACR2023 / ROR1 Targeted 4-1BB Stimulatory Bispecific Antibody, ABL102, Exhibits Potent in vitro and in vivo Antitumor Activity and Superior Safety Profile PDF 아이콘
16 ABL205 AACR2023 AACR2023 / Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronideprotected pyrrolobenzodiazepine payload PDF 아이콘
  • Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors

    링크정보 아이콘 PDF 아이콘

  • ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade

    링크정보 아이콘 PDF 아이콘

  • The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-1 antibody

    링크정보 아이콘 PDF 아이콘

  • ABL407, a LILRB4x4-1BB Bispecific Antibody with a Wild Type Fc, Exhibits Potent Antitumor Activity by Modulating Immune System in Multiple Ways Involving T cells, Myeloids, and Regulatory T cells

    링크정보 아이콘 PDF 아이콘

  • A Novel TIGIT and 4-1BB Bispecific Antibody, ABL112, Exhibits Potent in vitroand in vivo Antitumor Activity Through Dual Immune Modulation

    링크정보 아이콘 PDF 아이콘

  • PEGS Europe 2023 / ABL103, a novel B7-H4x4-1BB bispecific antibody, exerts potent antitumor activity and good safety profile via B7-H4-dependent 4-1BB activation with increased immune cell infiltration in tumor microenvironment

    링크정보 아이콘 PDF 아이콘

  • PEGS Europe 2023 / ROR1 targeted 4-1BB conditional bispecific antibody, ABL102, exhibits potent in vitro and in vivo antitumor activity and superior safety profile

    링크정보 아이콘 PDF 아이콘

  • CVB2023 / Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier

    링크정보 아이콘 PDF 아이콘

  • AACR2023 / ROR1 Targeted 4-1BB Stimulatory Bispecific Antibody, ABL102, Exhibits Potent in vitro and in vivo Antitumor Activity and Superior Safety Profile

    링크정보 아이콘 PDF 아이콘

  • AACR2023 / Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronideprotected pyrrolobenzodiazepine payload

    링크정보 아이콘 PDF 아이콘

123다음페이지로마지막페이지로